We all know the efficacy and functions of ensidipine, and scientific medication is guaranteed!

Enasidenib is a targeted therapy drug mainly used to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) carrying IDH2 gene mutations. IDH2 is an isocitrate dehydrogenase mutant enzyme that plays a key role in cell metabolism. It is abnormally expressed in some AML patients, leading to abnormal accumulation of a metabolite called 2-hydroxyglutarate (2-HG), thereby hindering the normal differentiation of leukemia cells.

As an IDH2 inhibitor, ensidipine can specifically inhibit the activity of mutant IDH2 enzymes, reduce the production of 2-HG, remove the blockage on hematopoietic cell differentiation, and enable abnormal immature leukemia cells to gradually differentiate into normal mature white blood cells, thus controlling the progression of the disease. This mechanism of action is different from traditional chemotherapy and brings new treatment options, especially for elderly patients or patients who cannot tolerate intensive chemotherapy, which has more clinical value.

The efficacy of ensidipine has been confirmed in multiple clinical trials. Some patients can obtain sustained complete remission or partial remission after treatment, and the efficacy usually gradually appears within 1 to 2 months after the start of treatment. In addition, ensidipine is administered orally once daily to facilitate long-term disease management for patients. Common side effects include hyperuricemia, nausea, loss of appetite, elevated bilirubin, leukocytosis, etc. Some patients may also develop a serious but controllable complication called "differentiation syndrome" during treatment, which requires close monitoring and prompt treatment.

In clinical practice, the use of ensidipine must be based on the diagnosis of IDH2 mutation. Therefore, genetic testing is an important prerequisite before medication. The approval of this drug marks the further advancement of precision therapy in the field of hematological tumors, and also provides new hope for survival for some AML patients who lack treatment options.

Reference materials:https://www.idhifa.com/